# Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC

Source: https://onco.cc/trials/nct07802834/  
OnCo record `nct07802834` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of zipalertinib in lung cancer, run by Stanford University, not yet recruiting.

## Summary

Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC is a phase 2, interventional study registered as NCT07802834 by Stanford University, with a registry enrolment figure of 42 participants, started 2026-11 and due to reach its primary completion in 2028-12. Interventions recorded: Zipalertinib. Conditions listed: EGFR; Lung Cancer (NSCLC); Non Small Cell Lung Cancer. Primary outcome: Molecular response rate at 12 weeks. Lung eligibility wording from the registry: "Histological documentation of NSCLC (squamous histology is permitted)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07802834
- Phase: 2
- Setting: Adjuvant ctDNA-Adapted Personalized Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
- Sponsor: Stanford University
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07802834: https://clinicaltrials.gov/study/NCT07802834

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Zipalertinib](https://onco.cc/drugs/zipalertinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07802834.json